# Contents

*Preface*  
Preface

*Contributors*  
Contributors

*About the Editors*  
About the Editors

---

## Part 1 Introduction and Basics of RNAi

1  
Mechanisms and Barriers to RNAi Delivery  
_Jiehua Zhou and John J. Rossi_

1.1 Introduction  
3

1.2 Barriers to Systemic RNAi Delivery  
5

1.3 Rational Design to Improve RNAi Efficacy  
6

1.4 Chemical Modifications to Enhance siRNA Stability and Reduce Immune Response  
7

1.5 Cellular Uptake and Intracellular Release of siRNA  
7

1.6 Combinatorial Targeting for Targeted RNAi Delivery  
8

1.7 Cell-Specific Aptamer-Functionalized Nanocarriers for RNAi Delivery  
9

1.8 The Clinical Development and Challenges of siRNAs Therapeutics  
10

1.9 Conclusion and Perspectives  
12

References  
12

## 2 Analysis of siRNA Delivery Using Various Methodologies  
_Yi Pei_

2.1 Introduction  
19

2.2 Checkpoints for Analyzing siRNA Delivery  
20

2.2.1 Circulation Checkpoint  
22

2.2.2 Organ or Tissue Checkpoint  
22

2.2.3 Cellular Checkpoint  
22

2.2.4 RISC Checkpoint  
23

2.2.5 Target mRNA Knockdown (Indirect Checkpoint)  
24

2.2.6 Protein and Outcome (Indirect Checkpoint)  
25

2.2.7 Safety (Indirect Checkpoint)  
26

2.3 Methods for Analysis of siRNA  
26

2.3.1 General Considerations  
26

2.3.2 Hybridization-Based (Non-Imaging) Methods  
28

2.3.3 Non-Hybridization-Based (Non-Imaging) Methods  
34

2.3.4 Imaging-Based (Non-Hybridization) Methods  
35

2.3.5 Imaging-Based (Hybridization) Methods  
37

---
3 Challenges and Opportunities in Bringing RNAi Technologies from Bench to Bed 45
Sandesh Subramanya and Lance Ford

3.1 Introduction 45
3.2 RNAi Mediator (siRNA or shRNA) 45
   3.2.1 siRNA 45
   3.2.2 Vector-derived shRNA 47
   3.2.3 miRNAs 49
3.3 Safety Issues of RNAi Mediators 50
   3.3.1 Immune Stimulation 50
   3.3.2 RNAi Overexpression 52
3.4 Efficacy of RNAi Mediators 52
   3.4.1 Therapeutic Response 52
3.5 RNAi Mediators in Clinical Trials 53
3.6 Conclusion 54
References 55

4 Nonclinical Safety Assessments and Clinical Pharmacokinetics for Oligonucleotide Therapeutics: A Regulatory Perspective 63
Shwu-Luan Lee, Paul Brown, Jian Wang and Robert T. Dorsam

4.1 Introduction 63
4.2 Unique Properties of Oligonucleotide-based Therapeutics 63
4.3 Regulation of Oligonucleotide-Based Therapeutics 65
   4.3.1 Submission to the FDA 65
   4.3.2 Review Process for Non-clinical Studies 67
   4.3.3 Regulatory Issues 74
   4.3.4 Clinical Pharmacokinetics 76
4.4 Conclusion 79
Disclaimer 79
Appendix 79
References 80

5 Role of Promoters and MicroRNA Backbone for Efficient Gene Silencing 83
Feng Li and Ram I. Mahato

5.1 Introduction 83
5.2 Promoters for shRNA Expression 84
   5.2.1 Constitutive Promoters 84
   5.2.2 Inducible Promoters 87
   5.2.3 Site Specific Promoters 93
5.3 miRNA-based shRNAs 96
8 Dendrimers in RNAi Delivery
Jose Luis Jiménez Fuentes, Paula Ortega, Sara Ferrando-Martínez,
Rafael Gómez, Manuel Leal, Javier de la Mata and
Mª Angeles Muñoz-Fernandez

8.1 Introduction 163
8.2 Challenges in RNAi Delivery 164
8.3 Dendrimers as Non Viral Vectors 166
  8.3.1 Dendritic Architectures 166
  8.3.2 Synthesis of Dendrimers 168
  8.3.3 Types of Dendrimers in Drug Delivery 169
References 179

9 Development of Pharmaceutically Adapted Mesoporous Silica Nanoparticles for siRNA Delivery
Wilson X. Mai, Tian Xia and Huan Meng

9.1 Introduction 187
9.2 Mesoporous Silica Nanoparticles as Novel Inorganic Nanocarriers for siRNA Delivery 188
  9.2.1 Discovery and Synthesis 188
  9.2.2 Surface Modification of MSNP for Nucleic Acid Delivery 190
  9.2.3 MSNP for Dual siRNA and Drug Delivery 191
  9.2.4 Improving in vivo Implementation of MSNP-Based Delivery Platform 196
  9.2.5 Design of Pharmaceutically Adapted MSNP via the Knowledge Generated by Discoveries at the Nano/Bio Interface 197
9.3 Safety Assessment of Nanocarrier and Design of Safe MSNP Carrier 199
  9.3.1 Safety of Nanocarriers 199
  9.3.2 Safe Design of MSNP Carrier 201
9.4 Summary 202
References 202

10 Environmentally-Responsive Nanogels for siRNA Delivery
Atsushi Tamura and Yukio Nagasaki

10.1 Introduction 207
  10.1.1 siRNA Delivery System 207
  10.1.2 Crosslinked Nanogels for siRNA Delivery 208
10.2 Reductive Environment-Responsive Disulfide Crosslinked Nanogels 209
10.3 Temperature-Responsive Nanogels 211
10.4 pH-Responsive Nanogels 212
  10.4.1 Acid-degradable Nanogels for Intracellular Release of siRNA 212
  10.4.2 Design of pH-Responsive PEGylated Nanogels with Endosomal Escape Ability 212
  10.4.3 Cytoplasmic Delivery of PEGylated Nanogel/siRNA Complexes 214
10.5 PEGylated and Partially Quaternized Polyamine Nanogels

10.5.1 Design of Quaternized Polyamine Nanogels

10.5.2 Enhanced Cellular Uptake of siRNA by Quaternized Polyamine Nanogels

10.5.3 Enhanced Gene-Silencing Activity of Quaternized Polyamine Nanogel/siRNA Complexes

10.6 Conclusions

References

11 Viral-Mediated Delivery of shRNA and miRNA

Fredric P. Manfredsson

11.1 Introduction

11.2 RNAi – A Brief Overview

11.3 shRNA or miRNA?

11.4 Rational Design

11.5 Viral Vectors

11.5.1 Recombinant Adeno-associated Virus (rAAV)

11.5.2 Retrovirus (RV)

11.5.3 Lentivirus (LV)

11.5.4 Adenovirus (AD)

11.5.5 Herpes Simplex Virus (HSV)

11.5.6 Baculovirus (BV)

11.5.7 Poxvirus

11.6 Tissue-specific Transduction

11.6.1 CNS

11.6.2 Ocular

11.6.3 Respiratory System

11.6.4 Liver

11.6.5 Skeletal Muscle

11.6.6 Heart

11.6.7 Systemic

11.6.8 Ex Vivo

11.6.9 Cell Culture

11.6.10 Transcription Cassettes

11.7 Applications of Virally Expressed shRNAs

11.7.1 Virally Mediated “Knockouts”

11.7.2 Concomitant Expression of Therapeutic Genes

11.8 Viral Gene Therapy in the Clinic

11.9 Conclusion

References

12 The Control of RNA Interference with Light

Simon H. Friedman

12.1 Introduction

12.2 The Importance of Gene Expression
Part 3 Applications of RNAi in Various Diseases

13 RNAi in Cancer Therapy
Cristian Rodriguez-Aguayo, Arturo Chavez-Reyes, Gabriel Lopez-Berestein and Anil K. Sood

13.1 Introduction
13.2 Therapeutic Opportunities for Noncoding RNAs
13.3 RNAs as Drugs
13.4 Overcoming Anatomical and Physiologic Barriers
  13.4.1 Intravascular Degradation
  13.4.2 Tissue and Intracellular Delivery
  13.4.3 Immune-mediated Toxic Effects
  13.4.4 Nanocarrier-mediated Toxic Effects
13.5 Advanced Delivery
  13.5.1 Localized siRNA Delivery
  13.5.2 Systemic siRNA Delivery
  13.5.3 Targeted siRNA Delivery
  13.5.4 Monitoring Delivery and Therapeutic Response
13.6 Clinical Experience
13.7 The Next Steps
Acknowledgments
References

14 Adenovirus-mediated siRNA Delivery to Cancer
Chae-Ok Yun

14.1 Introduction
  14.1.1 shRNA-expressing Vectors
  14.1.2 Adenovirus Vectors
14.2 shRNA-expressing Adenoviruses: Cancer Biological Studies and Therapeutic Implications
  14.2.1 Oncogene-targeted shRNA-expressing Ads
  14.2.2 shRNA-expressing Adenoviruses that Target Anti-apoptotic Genes
15 RNAi in Liver Diseases
Jiang Li, Jianqin Lu, Yifei Zhang, Mohammed Ghazwani, Peng Zhang, Xiang Gao and Song Li

15.1 Introduction 327
15.2 RNAi in Viral Hepatitis 328
  15.2.1 Hepatitis B 329
  15.2.2 RNAi of HBV Infection via siRNA/shRNA 330
  15.2.3 RNAi of HBV Infection via miRNAs 332
  15.2.4 Hepatitis C 333
  15.2.5 RNAi of HCV Infection via siRNA/shRNA 333
  15.2.6 RNAi of HCV Infection via miRNAs 335
15.3 RNAi in Hepatocellular Carcinoma 336
  15.3.1 RNAi of HCC via siRNA/shRNA 337
  15.3.2 RNAi of HCC via miRNAs 338
15.4 RNAi in Liver Fibrosis 340
  15.4.1 RNAi of Liver Fibrosis via siRNA/shRNA 341
  15.4.2 RNAi of Liver Fibrosis via miRNAs 343
15.5 Delivery Systems in RNAi 345
  15.5.1 Liver Anatomy 346
  15.5.2 Viral Delivery Systems 346
  15.5.3 Non-Viral Delivery Systems 347
  15.5.4 Cell-specific Targeting Strategies 348
  15.5.5 Cellular Events after the Uptake of Nucleic Acid-Carrier Complexes 349
  15.5.6 Lipid-based Delivery Systems 350
  15.5.7 Polymer-Based Systems 350
  15.5.8 Calcium Phosphate-Lipid Hybrid System 351
  15.5.9 Hydrophobitized Nucleic Acid Derivatives 351
  15.5.10 Targeted Delivery to Tumor Blood Vessels 351
15.6 Conclusion 352
Acknowledgments 353
References 353

16 Approaches to Delivering RNAi Therapeutics that Target Hepatitis B Virus
Carol Crowther, Mohube Betty Mowa, Abdullah Ely and Patrick Arbuthnot

16.1 Introduction 367
  16.1.1 RNAi Therapeutics 368
  16.1.2 Hepatitis B Virus as a Target for RNAi-based Gene Silencing 369
16.2 Vectors Suitable for Hepatic Delivery of HBV Gene Silencers

16.2.1 Viral Vectors
16.2.2 Nonviral Vectors

16.3 Conclusions
Acknowledgments
References

17 RNAi in Respiratory Diseases
Ciara Kelly, Awadh B. Yadav, Paul J. McKiernan, Catherine M. Greene and Sally-Ann Cryan

17.1 Introduction
17.2 Respiratory Disease and RNA Interference
17.2.1 RNAi in Lung Cancer
17.2.2 RNAi to Treat Respiratory Infections
17.2.3 RNAi in Inflammatory Lung Disease

17.3 Delivery and Development of RNAi Therapies for Respiratory Disease
17.3.1 Inhalation of RNA-medicines
17.3.2 Chemical Modifications of siRNA
17.3.3 RNAi Vectors
17.3.4 RNAi Therapy *In Vivo*

17.4 Conclusions
Acknowledgements
References

18 RNAi in Ocular Diseases
Andrey Turchinovich, Georg Zoidl and Rolf Dermietzel

18.1 Introduction
18.2 The Principle of RNAi
18.3 *In vivo* Delivery of siRNA
18.4 Delivery of siRNA into the Eye
18.4.1 Routes for Ocular Delivery of siRNA
18.4.2 Delivery of Naked siRNA
18.4.3 Delivery of siRNA Using Carriers
18.4.4 Viral Delivery of shRNA

18.5 Conclusions
Abbreviations
References

19 microRNAs as Therapeutic Agents and Targets
D.S. Karolina and K. Jeyaseelan

19.1 Introduction
19.2 miRNA Therapeutics
19.2.1 Therapeutic miRNA Inhibition
19.2.2 Therapeutic miRNA Mimicry
20 Delivery of MicroRNA Sponges for Interrogation of MicroRNA Function In Vitro and In Vivo

Jiakai Lin and Shu Wang

20.1 MicroRNA Loss-of-Function Studies 483
20.2 Considerations in MicroRNA Sponge Design 486
   20.2.1 Vector 486
   20.2.2 Promoter 487
   20.2.3 Reporter Gene 488
   20.2.4 MicroRNA Binding Sites 488
20.3 Advantages and Limitations of MicroRNA Sponge over Other MicroRNA Loss-of-Function Strategies 489
20.4 Interrogating MicroRNA Function via Transient MicroRNA Sponge Expression 493
20.5 Interrogating MicroRNA Function via Stable MicroRNA Sponge Expression 494
   20.5.1 MicroRNA and Cell Differentiation 494
   20.5.2 MicroRNAs in Disease Development 495
20.6 Utility of MicroRNA Sponge in Living Organisms 496
   20.6.1 MicroRNA Knockdown in Plants 496
   20.6.2 MicroRNA Knockdown in Mouse 497
   20.6.3 MicroRNA Knockdown in Drosophila Melanogaster 498
20.7 Future Perspectives 498
References 499

Index 505